2024.12.Brigatinib,Alunbrig,Markets and News,API,Brigatinib,1197953-54-0
Abstract:
Brigatinib, a potent anaplastic lymphoma kinase (ALK) inhibitor, was developed as a second-line therapy for patients with ALK-positive non-small cell lung cancer (NSCLC). Originally researched by ARIAD Pharmaceuticals and later acquired by Takeda, Brigatinib's approval timeline, market launch, and sales data provide insights into its commercial success and therapeutic efficacy. This paper examines Brigatinib’s clinical development, approval in global markets, particularly in China, and its market competition with other ALK inhibitors. Additionally, the paper explores the impact of generic drug competition and reviews ongoing developments surrounding this drug. Through a thorough analysis of Brigatinib’s trajectory, we assess its role in advancing cancer treatment and its potential future in the oncology landscape..jpg)
Keywords:
Brigatinib, ALK inhibitors, non-small cell lung cancer (NSCLC), market competition, generic drugs, sales, Takeda, ARIAD Pharmaceuticals, China,API,Brigatinib,1197953-54-0
Introduction:
Brigatinib (trade name Alunbrig) is a targeted therapy developed for patients with ALK-positive non-small cell lung cancer (NSCLC), a genetic mutation that affects a subset of lung cancer patients. As an anaplastic lymphoma kinase (ALK) inhibitor, Brigatinib works by blocking the activity of the ALK protein, which is responsible for the growth of cancer cells. It is used primarily in patients with advanced or metastatic ALK-positive NSCLC, particularly after resistance to first-line therapies like crizotinib. Developed by ARIAD Pharmaceuticals and later acquired by Takeda, Brigatinib has become a key drug in the treatment of ALK-positive NSCLC.
This paper provides a detailed exploration of Brigatinib's development, approval, market impact, and competition, especially in China, as well as its positioning within the broader oncology landscape.
Text:
1. Development and Approval Timeline
Brigatinib was developed by ARIAD Pharmaceuticals, a company known for its innovative therapies targeting cancers driven by genetic mutations. In 2017. the U.S. Food and Drug Administration (FDA) approved Brigatinib for use in patients with ALK-positive NSCLC, specifically for those who had progressed on or were intolerant to crizotinib. The FDA's approval was based on the results of the ALTA trial, which demonstrated the drug’s efficacy in terms of progression-free survival (PFS).
Brigatinib’s approval in China was granted in 2019 by the National Medical Products Administration (NMPA). The approval came at a time when China was increasingly focused on improving treatment options for lung cancer, one of the most prevalent and deadly cancers in the country.
In addition to the U.S. and China, Brigatinib has been approved in numerous other global markets, including Europe and Japan, where it is used as a second-line therapy for ALK-positive NSCLC patients.
2. Mechanism of Action
Brigatinib is a selective ALK inhibitor that works by blocking the kinase activity of ALK proteins, which play a key role in the uncontrolled growth of cancer cells. In ALK-positive NSCLC, these proteins are often aberrantly activated, driving tumor proliferation. By inhibiting ALK, Brigatinib halts the growth of cancer cells, leading to tumor regression in patients with this mutation. Additionally, Brigatinib is effective in overcoming some forms of resistance to earlier ALK inhibitors, such as crizotinib, making it a key therapeutic option for resistant cases.
3. Clinical Efficacy and Safety
The approval of Brigatinib was based on results from the ALTA trial, which compared Brigatinib to crizotinib in patients with ALK-positive NSCLC. The trial demonstrated that Brigatinib significantly improved progression-free survival (PFS) and overall response rate (ORR) compared to crizotinib, especially in patients who had previously failed on crizotinib therapy. Furthermore, Brigatinib has shown effectiveness in patients with brain metastases, a common complication of ALK-positive NSCLC, with an improved central nervous system (CNS) response rate compared to older therapies.
In terms of safety, Brigatinib is associated with certain side effects, most notably pulmonary adverse events, including pneumonitis, which can be severe or even fatal. Other common side effects include hypertension, gastrointestinal symptoms, and elevated liver enzymes. Patients are monitored closely for these adverse events during treatment.
4. Global Market and Sales
Brigatinib has seen significant global sales since its approval, with strong performance in the U.S., Japan, and Europe. Takeda Pharmaceuticals, which acquired ARIAD Pharmaceuticals in 2017. continued to push Brigatinib’s adoption in various markets. According to Takeda’s annual financial reports, the drug has achieved substantial sales figures, with annual revenue reaching hundreds of millions of USD in its early years post-launch.
While Brigatinib’s sales have been strong in these markets, its market share is still challenged by the competition from other ALK inhibitors, such as crizotinib, alectinib, and lorlatinib. These drugs are also approved for treating ALK-positive NSCLC and offer different efficacy and safety profiles.
5. Sales in China
China, with one of the highest rates of lung cancer worldwide, has seen growing demand for ALK inhibitors. Brigatinib’s approval in 2019 was a crucial step in providing more treatment options for Chinese patients with ALK-positive NSCLC. Takeda focused on expanding Brigatinib’s market presence by collaborating with local healthcare providers and raising awareness among oncologists about its benefits over first-line therapies like crizotinib.
Sales of Brigatinib in China have shown steady growth, especially in the years following its launch, and it has become one of the most widely used ALK inhibitors in the region. However, it faces stiff competition from both branded and generic alternatives.
6. Market Competition
The ALK inhibitor market is highly competitive, with multiple drugs approved for treating ALK-positive NSCLC. Crizotinib, the first ALK inhibitor, remains widely used, but newer second- and third-generation inhibitors, including alectinib, ceritinib, and lorlatinib, offer improved efficacy and tolerability.
Brigatinib distinguishes itself from these competitors through its demonstrated ability to overcome resistance mutations in the ALK gene, particularly the L1196M mutation, which is associated with crizotinib resistance. It also has an improved CNS penetration profile, making it effective in patients with brain metastases.
Despite these advantages, the drug's relatively higher price compared to generic crizotinib can limit its uptake in some markets, particularly where access to healthcare is a challenge. In the face of increasing competition, Brigatinib's market share could face pressure as generics begin to enter the market.
7. Impact of Generic Drugs
The development of generic versions of older ALK inhibitors, particularly crizotinib, is having a significant impact on the ALK inhibitor market. Generic crizotinib has lowered the treatment cost for patients, which could potentially affect the market uptake of newer and more expensive drugs like Brigatinib.
As patents for newer ALK inhibitors expire, the market will likely see the introduction of generic versions of these drugs as well, leading to even more price competition. However, despite the price pressures, drugs like Brigatinib may continue to be preferred in cases where resistance to older therapies has occurred or when patients require more effective CNS penetration.
8. Ongoing Developments
Research continues into the potential of Brigatinib in combination with other therapies, including immunotherapies and other targeted agents. Early clinical trials suggest that combining Brigatinib with checkpoint inhibitors or other molecularly targeted treatments may offer enhanced efficacy in treating advanced-stage lung cancer.
Furthermore, Takeda is working to expand Brigatinib’s use beyond NSCLC, exploring its potential in treating other cancers that exhibit ALK gene rearrangements, such as inflammatory myofibroblastic tumors (IMTs), which could increase the drug's market applicability.
Conclusion:
Brigatinib has emerged as a leading therapy for ALK-positive non-small cell lung cancer, offering significant benefits over older treatments like crizotinib, particularly in overcoming resistance and improving CNS response rates. The drug's strong performance in global markets, particularly in China, highlights its importance in the treatment landscape. However, competition from other ALK inhibitors, including generics, may affect its market position in the long term. Ongoing research into combinations and new indications could further solidify Brigatinib’s role in oncology, making it a valuable therapeutic option for patients with various cancers driven by ALK mutations.
References:
Shaw AT, Kim DW, Mehra R, et al. Brigatinib versus Crizotinib in ALK-positive non-small-cell lung cancer. NEJM. 2017; 377(9):829-838.
Takeda Pharmaceutical Company Limited. Annual Report 2023.
Li X, Liu Y, Huang H, et al. Brigatinib in ALK-positive non-small cell lung cancer: Efficacy and safety in Chinese patients. Cancer Research and Treatment. 2020; 52(3): 916-924.
National Medical Products Administration. NMPA Drug Approval Database. 2019.
Wikipedia contributors. Brigatinib. Wikipedia, The Free Encyclopedia.
Additional Information:
Active Pharmaceutical Ingredient 1197953-54-0
Brigatinib, (chemical grade, purity ≥99.0%) are currently supplied by our company. [Own compliance factory, fully support factory audit] For details, you can call the bottom line to get the latest price of the product!
Disclaimer:Products are available only to countries without valid patent protection. Products under patent rights are sold exclusively for experimental or registration purposes, complying with national applicable laws. They are not intended for human use, and buyers are responsible for evaluating patent situations in their respective markets.
Photo Credit:Images from Pexels (for illustration purposes only). Apologies for any inadvertent infringement; corrections and feedback are welcome.
Note: This content is for informational purposes only and does not constitute investment or medical advice.
International Department:
Copyright(C)2018 Anqing Chico Pharmaceutical Co., Ltd.
Supported byChinaChemNet
